-
2026-10-28
IND Approval: GenSci136 Advances into Sj?gren's SyndromeLearn More
-
2026-10-22
Phase 3 trial in China successfully confirms ACARIZAX? safety and efficacy in patients with house dust mite allergyLearn More
-
2026-10-10
GenSci's Oncology Innovation: NDA Approval Secured for Prostate CancerLearn More
-
2026-10-09
GenSci's Two Innovations Received IND Clearance from NMPALearn More
-
2026-09-03
GenSci Showcases Innovation at CPHI Korea 2026Learn More
-
2026-08-13
GenSci's Ophthalmology Pipeline: IND Approval Secured for Three IndicationsLearn More
-
2026-07-31
GenSci144, a Novel SLC6A19 Inhibitor, Receives IND Approval from NMPALearn More
-
2026-07-30
Gensci's VEGFR2 mAb NDA Accepted by NMPALearn More
-
2026-07-30
GenSci098 Receives FDA Fast Track Designation and Advances into Phase 2 Clinical TrialsLearn More
-
2026-06-24
GenSci's Triptorelin Acetate for Injection (II) Secures NMPA Approval for Central Precocious PubertyLearn More
-
2026-06-04
GenSci: Two Innovations Granted IND Clearance by FDALearn More